raav2 Search Results


92
ATCC vr 1616
Vr 1616, supplied by ATCC, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/rAAV2+RSS%3B+Reference+material/pmc07196056-152-6-5
Average 92 stars, based on 1 article reviews
vr 1616 - by Bioz Stars, 2026-11
92/100 stars
  Buy from Supplier

86
Genechem raav2
Raav2, supplied by Genechem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/9+camkii+drd1+egfp+raav2+rnai/10__1172_slash_jci196944-282-15-24
Average 86 stars, based on 1 article reviews
raav2 - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

95
Addgene inc paav2 retro
Paav2 Retro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/rAAV2-retro+helper+(Plasmid+%2381070)/10__1016_slash_j__jphs__2025__06__004-37-18-22
Average 95 stars, based on 1 article reviews
paav2 retro - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

96
PackGene Biotech lnc aav2 cas9
Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection <t>of</t> <t>AAV2-mCherry</t> (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).
Aav2 Cas9, supplied by PackGene Biotech lnc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/AAV2+Vector+Production/pmc12930510-150-8-14
Average 96 stars, based on 1 article reviews
aav2 cas9 - by Bioz Stars, 2026-11
96/100 stars
  Buy from Supplier

94
Addgene inc raav2 retro
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Raav2 Retro, supplied by Addgene inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/rAAV2-retro+(Plasmid+%2383283)/bio_rxiv__488585-116-13-26
Average 94 stars, based on 1 article reviews
raav2 retro - by Bioz Stars, 2026-11
94/100 stars
  Buy from Supplier

90
Gensight Inc raav2.7m8-cag-chrimsonr-tdtomato (gs030)
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Raav2.7m8 Cag Chrimsonr Tdtomato (Gs030), supplied by Gensight Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/raav2+2+nd4/pmc07352801__ijms___21___04197___s001-38-0-0
Average 90 stars, based on 1 article reviews
raav2.7m8-cag-chrimsonr-tdtomato (gs030) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Janvier Labs modified raav2-gfp
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Modified Raav2 Gfp, supplied by Janvier Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/unmodified+raav2/us11382988-541-15-13
Average 90 stars, based on 1 article reviews
modified raav2-gfp - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sangamo Inc bdd-fviii
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Bdd Fviii, supplied by Sangamo Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/raav2+6/pmc07132613-28-8-0
Average 90 stars, based on 1 article reviews
bdd-fviii - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Applied Genetic Technologies Corporation raav2-cb-hrpe65
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Raav2 Cb Hrpe65, supplied by Applied Genetic Technologies Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/raav2+cbhrpe65/pmc07701157-63-9-11
Average 90 stars, based on 1 article reviews
raav2-cb-hrpe65 - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Promega β-galactosidase assay raav-2-lacz
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
β Galactosidase Assay Raav 2 Lacz, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/%CE%B2+galactosidase+assay+raav+2+lacz/pmc01606626-35-9-44
Average 90 stars, based on 1 article reviews
β-galactosidase assay raav-2-lacz - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
VectorBuilder GmbH raav2-colq-myc
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Raav2 Colq Myc, supplied by VectorBuilder GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/or+containing+only+the+sequence+coding+for+egfp++raav2+egfp+/pm37356721-337-40-55
Average 90 stars, based on 1 article reviews
raav2-colq-myc - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Albaugh LLC raav2-retro
AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 <t>(rAAV2-retro</t> and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.
Raav2 Retro, supplied by Albaugh LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/raav2/raav2+retro/pmc09559170-45-2-21
Average 90 stars, based on 1 article reviews
raav2-retro - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

Journal: ACS Synthetic Biology

Article Title: Enhanced Epigenetic Modulation via mRNA-Encapsulated Lipid Nanoparticles Enables Targeted Anti-inflammatory Control

doi: 10.1021/acssynbio.5c00188

Figure Lengend Snippet: Co-delivery of Myd88 repressor ZFR11 and gene therapy related antigen modulates humoral immunity in AAV preimmunized mice. (A) Schematic representation of experimental design. C57BL/6J mice received two retro-orbital injections of AAV2-GFP (5 × 10 11 GC) 2 weeks apart. Two weeks later, mice were administered weekly doses of LNP-encapsulated mRNA (0.7 mg kg –1 ) encoding either ZFR11-VP1-mCherry ( N = 10), VP1 only ( N = 10), or no LNP/PBS control ( N = 6) for 4 weeks. Two weeks after the final vaccination, mice received a single intravenous coinjection of AAV2-mCherry (5 × 10 11 GC) and ZFR11-LNP (0.7 mg kg –1 ). Analyses were performed 3 weeks post-AAV2 challenge. (B) qRT-PCR analysis of mCherry expression in liver and lung tissues ( N = 8–10 mice per treatment group, N = 6 for PBS). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant (C) Left: Representative immunohistochemical staining for mCherry in liver sections. Right: Quantification of mCherry staining intensity (ZFR11-VP1-mCherry-306O 10 : N = 9, PBS: N = 5, staining negative control/mCherry uninjected: N = 2). Data are presented as mean ± SEM Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered statistically significant. (D) ELISA measurement of plasma anti-AAV2 total IgG and IgG2b levels. Results shown as fold change in optical density at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 per treatment group, N = 6 for PBS). Statistical analysis was performed using one-way ANOVA followed by Dunnett’s multiple comparisons test. * P ≤ 0.05 was considered significant. (E) ELISA measurement of serum anti-AAV2 neutralizing antibody levels showing a 32% reduction in the ZFR11-VP1-mCherry group compared to VP1 control at day 35 (2 weeks postvaccination) relative to day 0 (prevaccination baseline) ( N = 9–10 mice per treatment group, N = 6 mice for PBS). Statistical analysis was performed using the unpaired parametric t test. * P ≤ 0.05 was considered significant. (F) Time-point analysis of plasma total IgG, IgG2b, and neutralizing antibodies titers in Relative Light Units (RLU) at day 0 (prevaccination baseline), day 35 (2 weeks postvaccination), and day 45 (10 days after AAV2-mCherry rechallenge) ( N = 9–10 per treatment group).

Article Snippet: Following validation, these constructs served as templates for AAV2-Cas9 and AAV2-mCherry viral production by PackGene Biotech, LLC.

Techniques: Control, Quantitative RT-PCR, Expressing, Immunohistochemical staining, Staining, Negative Control, Enzyme-linked Immunosorbent Assay, Clinical Proteomics

AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 (rAAV2-retro and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.

Journal: bioRxiv

Article Title: Improved yield of AAV2 and rAAV2-retro serotypes following sugar supplementation during the viral production phase

doi: 10.1101/488585

Figure Lengend Snippet: AAV yields after sucrose treatment in a large scale production. AAVpro 293T cells were triple transfected with a transfer plasmid, a plasmid encoding rep and serotype specific cap genes and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M sucrose. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. For each serotype between 2 (AAV2) and 4 (rAAV2-retro and AAV5) different preps were prepared and the range and average number of AAV genome copies (GC) calculated and plotted, A. B, the average fold change of sucrose to untreated viral prep was calculated and plotted.

Article Snippet: Given these promising results, we decided to test the sucrose supplementation strategy on rAAV2-retro and AAV5 yields as these serotypes are routinely prepared and distributed by Addgene.

Techniques: Transfection, Plasmid Preparation, Purification, Concentration Assay, Buffer Exchange

AAVpro 293T cells were triple transfected with a plasmid encoding jGCaMP7f (Addgene number 104488), a plasmid encoding rep and rAAV2-retro cap genes (Addgene number 81070) and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M of the indicated sugar. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. A, following buffer exchange, the level of sucrose or sorbitol was measured in the final preparations as compared to a standards of known concentration. B, Neuro2a cells were transduced with approximately 1.5 × 10 6 vector particles per cell from the untreated and sucrose treated viral preparations. GCaMP7f expression was assessed 96h post transduction. C, purity of the final untreated and sucrose treated preparations was assessed via SDS-PAGE followed by silver staining.

Journal: bioRxiv

Article Title: Improved yield of AAV2 and rAAV2-retro serotypes following sugar supplementation during the viral production phase

doi: 10.1101/488585

Figure Lengend Snippet: AAVpro 293T cells were triple transfected with a plasmid encoding jGCaMP7f (Addgene number 104488), a plasmid encoding rep and rAAV2-retro cap genes (Addgene number 81070) and a plasmid encoding the adenoviral helper sequences. The following day media was replaced with fresh DMEM with or without 0.1M of the indicated sugar. Cells and media were harvested 96h post transfection and viral particles purified via iodixanol gradient ultracentrifugation followed by concentration and buffer exchange. A, following buffer exchange, the level of sucrose or sorbitol was measured in the final preparations as compared to a standards of known concentration. B, Neuro2a cells were transduced with approximately 1.5 × 10 6 vector particles per cell from the untreated and sucrose treated viral preparations. GCaMP7f expression was assessed 96h post transduction. C, purity of the final untreated and sucrose treated preparations was assessed via SDS-PAGE followed by silver staining.

Article Snippet: Given these promising results, we decided to test the sucrose supplementation strategy on rAAV2-retro and AAV5 yields as these serotypes are routinely prepared and distributed by Addgene.

Techniques: Transfection, Plasmid Preparation, Purification, Concentration Assay, Buffer Exchange, Transduction, Expressing, SDS Page, Silver Staining

A, AAVpro 293T were left untreated (top panels) or treated with 0.1M sucrose (bottom panels) for 72 hours. The level of endocytosis of untreated and sucrose-treated cells was assessed via internalization of the pH sensitive pHrodo green dextran dye. B, AAVpro 293T cells were transduced with CAG-GFP rAAV2-retro in the absence (top panels) or presence (bottom panels) of 0.1M sucrose. 72h later, cells GFP expression was assessed by direct fluorescence.

Journal: bioRxiv

Article Title: Improved yield of AAV2 and rAAV2-retro serotypes following sugar supplementation during the viral production phase

doi: 10.1101/488585

Figure Lengend Snippet: A, AAVpro 293T were left untreated (top panels) or treated with 0.1M sucrose (bottom panels) for 72 hours. The level of endocytosis of untreated and sucrose-treated cells was assessed via internalization of the pH sensitive pHrodo green dextran dye. B, AAVpro 293T cells were transduced with CAG-GFP rAAV2-retro in the absence (top panels) or presence (bottom panels) of 0.1M sucrose. 72h later, cells GFP expression was assessed by direct fluorescence.

Article Snippet: Given these promising results, we decided to test the sucrose supplementation strategy on rAAV2-retro and AAV5 yields as these serotypes are routinely prepared and distributed by Addgene.

Techniques: Transduction, Expressing, Fluorescence